Given the ability of JOC-x to specifically localize to tumors overexpressing DSG2 and the known anti-tumor effects of poly(I:C), we envision that the JOC-poly(I:C) conjugate would exhibit enhanced targeting of tumors, increased potency, and overall less toxicity due to reduced binding to healthy tissues expressing TLR3 receptors and DSG2 that is properly sequestered in tight junctions. Here, DSG2 is linked to neoplasm.